Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 1;183(1):4-10.
doi: 10.1016/j.cell.2020.09.005. Epub 2020 Sep 3.

Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study

Lewis Au  1 , Laura Amanda Boos  2 , Anthony Swerdlow  3 , Fiona Byrne  4 , Scott T C Shepherd  1 , Annika Fendler  4 , Samra Turajlic  5 ; CAPTURE investigators
Affiliations
Review

Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study

Lewis Au et al. Cell. .

Abstract

The SARS-CoV-2 pandemic has posed a significant challenge for risk evaluation and mitigation among cancer patients. Susceptibility to and severity of COVID-19 in cancer patients has not been studied in a prospective and broadly applicable manner. CAPTURE is a pan-cancer, longitudinal immune profiling study designed to address this knowledge gap.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests S.T. reports grants and speaker fees from Roche Tissue Diagnostics. L.A., L.B., F.B., S.S., A.F., A.S. have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Schematic Representation of Immune Changes in Cancer Patients that Can Impact Immune Response during a SARS-CoV-2 Infection (A) Cancer type, stage, and therapy (including surgery, systemic anti-cancer therapy, and other anti-cancer interventions) can result in varying degrees of immune suppression, which conceivably may lead to increased clinical susceptibility to SARS-CoV-2 infection and COVID-19 illness. (B) Examples of the varied mechanisms by which host immunity (innate or humoral/cellular adaptive immunity) is altered, with potential influence on the immune response as well as immunopathologic hyperinflammation of COVID-19. SACT, systemic anti-cancer therapy; Rx, other anti-cancer treatments including radio-, hormonal, targeted, and cellular therapy; ADT, androgen deprivation therapy; CAR-T, chimeric antigen receptor T cell.
Figure 2
Figure 2
Overview of CAPTURE Study Procedures and Analysis Plans Patients are recruited into study arms A or B, and follow-up schedules are bespoke to their COVID-19 status and accounts for their clinical visit/treatment requirements; while healthcare workers are recruited and followed-up according to schedule as outlined. Comprehensive demographic, epidemiological, and clinical data will be collected along with swabs and blood samples. Diagnostic assays will be performed for all participants and will inform selection of samples for detailed immune monitoring and next-generation sequencing. Standard operating procedure documents (for local sample collection, processing, and storage) will be implemented in additional institutions, and sample analyses will be centralized to ensure standardization.
See this image and copyright information in PMC

References

    1. COVIDSurg Collaborative Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020;396:27–38. - PMC - PubMed
    1. Dai M., Liu D., Liu M., Zhou F., Li G., Chen Z., Zhang Z., You H., Wu M., Zheng Q., et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak. Cancer Discov. 2020;10:783–791. - PMC - PubMed
    1. Garassino M.C., Whisenant J.G., Huang L.C., Trama A., Torri V., Agustoni F., Baena J., Banna G., Berardi R., Bettini A.C., et al. TERAVOLT investigators COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21:914–922. - PMC - PubMed
    1. Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R., Rawlings S.A., Sutherland A., Premkumar L., Jadi R.S., et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181:1489–1501.e15. - PMC - PubMed
    1. Kuderer N.M., Choueiri T.K., Shah D.P., Shyr Y., Rubinstein S.M., Rivera D.R., Shete S., Hsu C.Y., Desai A., de Lima Lopes G., Jr., et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–1918. - PMC - PubMed

Publication types

Substances